Introduction: Coronary heart disease, stroke,
concentration of valsartan by approximately 6%. These effects were not considered clinically meaningful. In addition, dapagliflozin had no effect on the pharmacokinetics of either digoxin or warfarin. The pharmacodynamics of warfarin were also unaffected by dapagliflozin.
INTRODUCTION
The global burden of diabetes is daunting:
there were an estimated 285 million sufferers worldwide in 2010 [1, 2] , and this number is predicted to rise to 438 million by 2030. Type 2 diabetes mellitus (T2DM) is the predominant form, accounting for approximately 90% of all cases of diabetes [3] . T2DM occurs primarily in economically developing and newly industrialized countries, where it has reached epidemic proportions, largely as a result of urbanization, associated lifestyle changes, and consequent obesity [4] . Increasing body mass index (BMI) is associated with an increased prevalence of T2DM, dyslipidemia, and hypertension [5] . The simultaneous achievement of glycemic, blood pressure, and low-density lipoprotein targets is pivotal to the management of T2DM to avoid cardiovascular disease and premature death [6] .
The medical management of hyperglycemia in T2DM concentrates not only on the use of lifestyle-directed interventions, but also on pharmacologic interventions, such as insulin, sulfonylureas, and metformin [7] . Recently, the search for insulin-independent mechanisms for glycemic control in T2DM has resulted in the development of a novel approach -inducing renal glucose excretion pharmacologically by inhibiting the reabsorption of glucose from the glomerular filtrate. Under conditions of normoglycemia, virtually all glucose in the glomerular filtrate is reabsorbed in the proximal tubules, mostly via sodium glucose co-transporter-2 (SGLT2) [8] . Dapagliflozin is a first-in-class oral, selective, reversible inhibitor of SGLT2 in development for the treatment of T2DM [9] . Studies in healthy and diabetic rats have demonstrated that dapagliflozin improves glucose homeostasis [10] , and dosedependent urinary glucose excretion is induced by dapagliflozin in humans [11, 12] . Clinical studies have also demonstrated the efficacy of dapagliflozin in the treatment of T2DM [12] [13] [14] [15] [16] [17] .
There is a clear epidemiologic and pathophysiologic link between both microand macro-vascular disease and T2DM [18] .
Coronary heart disease, stroke, and peripheral vascular disease are the most common causes of mortality in patients with T2DM [19] .
Cardiovascular disease, such as atherosclerosis or congestive heart failure, is often present in patients with T2DM [20, 21] . clinicaltrials.gov identifier: NCT00904176).
In-vitro pharmacologic studies suggest that dapagliflozin is primarily metabolized via glucuronidation by uridine diphosphate glucuronyl transferase (UGT1A9 enzyme). Under in-vitro conditions, dapagliflozin was not found to be an inhibitor or an inducer of human cytochrome (CYP) isozymes and, although it proved to be a substrate for P-glycoprotein (P-gp), it has not been demonstrated to be a significant P-gp inhibitor. Thus, dapagliflozin was not anticipated to significantly affect the pharmacokinetics of co-administered drugs that are CYP or P-gp substrates [22] .
Valsartan is minimally metabolized in humans, with no involvement of CYP isozymes [23] . In addition, there is no evidence to indicate that its rapid absorption is affected by P-gp.
Simvastatin is metabolized predominantly via CYP3A4 [24] and, while a variety of simvastatin drug-drug interactions have been observed, significant interactions that are clinically evident remain rare [25] . S-warfarin, the enantiomer that is primarily responsible for warfarin's anticoagulant effects, is principally metabolized by CYP2C9 [26] . The metabolism of digoxin is reported to be minimal and is also not dependent on CYP isozymes. Digoxin is excreted in urine and bile largely unchanged [27] . The gastrointestinal absorption of digoxin, however, does appear to be mediated by P-gp [28] .
Small alterations in the absorption, free fraction, or clearance of these cardiovascular drugs -and in particular warfarin and digoxin, both of which have a narrow therapeutic index -could lead to a decrease in therapeutic effect, or to potential toxicity. Therefore, although pharmacokinetic interactions are not predicted on the basis of the routes of metabolism, it is important to confirm a lack of clinically significant interaction via clinical pharmacokinetic studies. In addition, as there is evidence for pharmacodynamic interaction of some drugs (for example, rosuvastatin [29] ) with warfarin without concomitant changes in pharmacokinetics, pharmacodynamic parameters were also evaluated for warfarin (plasma prothrombin time) in the presence and absence of dapagliflozin.
MATERIALS AND METHODS

Subjects
For both studies, male and female subjects deemed to be healthy on the basis of medical history, physical examination, 12-lead electrocardiogram, and clinical laboratory evaluations were eligible.
Other inclusion criteria were age in the range of 
Study 1
This was an open-label, randomized, fiveperiod, five-treatment, unbalanced crossover study (Fig. 1a) . Twenty-four enrolled subjects 
Study 2
An open-label, randomized, two-period, two-treatment crossover study ( for simvastatin ≤2.5% and ≤5.8% (0.1-60 ng/mL);
for simvastatin acid ≤3.5% and ≤8.5%
(0.05-20 ng/mL); and for valsartan ≤3.6%
and ≤5.1% (10-8000 ng/mL). For study 2 the dapagliflozin analysis was conducted at Cedra, and the warfarin and digoxin assays were conducted at PPD (Richmond, VA, USA). The between-run and within-run variability (LLOQ -ULOQ) of the assays were: for dapagliflozin ≤6.3% and ≤3.9% (1-200 ng/mL); for R-warfarin ≤3.4% and ≤4.7% (5-1000 ng/mL); for S-warfarin ≤3.0% and ≤5.0% (5-1000 ng/mL); and for digoxin ≤8.4% and ≤14.2% (0.1-50 ng/mL). 
Pharmacokinetic and Pharmacodynamic Evaluation
Statistical Methods for Pharmacokinetic and Pharmacodynamic Analyses
The sample sizes for the studies were not based on specific statistical power considerations.
However, for study 1, data from 22 subjects would provide at least 90% confidence that the estimated ratios of geometric means for simvastatin C max and AUC 0-τ , with or without dapagliflozin, would be within 17% and 24%
of the true population ratios. For cohort 1 of study 2, including 12 subjects provides at least 90% confidence that the estimated ratios of geometric means for S-warfarin C max and AUC 0-τ , with or without dapagliflozin, would be within 10% and 11% of the true population ratios.
For cohort 2 of study 2, including 14 subjects provides at least 90% confidence that the estimated ratios of geometric means for digoxin C max and AUC 0-τ , with or without dapagliflozin, would be within 12% and 5% of the true population ratios.
To assess the effects of co-administration, 
Safety Profile
Subjects were monitored throughout the study for all adverse events, with information recorded on intensity and relationship to study drug in the opinion of the investigator. Any serious adverse event was also recorded. Vital signs (body temperature, respiratory rate) and seated blood pressure and heart rate, measured after the subject had been seated quietly for ≥5 minutes, were evaluated at the screening visit and prior to dosing on days 1, 2, and 3 of each period for study 1, and on days 1, 2, 5, and 8 for periods 1 and 2 for study 2. Vital signs were also recorded on day -1 of periods 2, 3, 4, and 5 for study 1, as well as at study discharge for studies 1 and 2.
In addition, blood pressure was measured at the time of pharmacokinetic sample collection.
RESULTS
Subject Demographics
In study 1, 23 subjects were male and one was female; 63% were African American, 29%
were white, and 8% were of other ethnicity.
The mean age was 32 years (range, 21-43 years) and the mean BMI was 26.8 (range, 19.6-31.6).
Twenty-three subjects completed study 1. One subject discontinued the study because of agitation; this subject subsequently went on to have a serious adverse event.
In study 2, all 30 subjects were male. The predominant ethnic group was white (63%), 
Pharmacokinetics
Dapagliflozin
The mean plasma concentration versus time profiles for dapagliflozin, with and without simvastatin or valsartan, were comparable (Fig. 2) . No clinically meaningful changes in the pharmacokinetic parameters of dapagliflozin were observed when it was administered with either simvastatin or valsartan ( Table 1 There was no clinically meaningful change in simvastatin C max in the presence of dapagliflozin.
The 90% CI for the simvastatin C max ratio fell within the usual no-effect range ( Table 2 ). The The geometric mean for valsartan C max and AUC 0-τ changed by no more than 6%.
When valsartan was co-administered with dapagliflozin, the 90% CI for the valsartan C max ratio fell slightly outside the lower bound of the usual no-effect range (0.76), and the upper limit of the 90% CI for the valsartan AUC 0-τ ratio was slightly extended beyond the usual no-effect range (1.30).
Warfarin and Digoxin
Mean plasma concentration versus time profiles for R-warfarin, S-warfarin, and digoxin, with and without dapagliflozin, are shown in Fig. 4 .
The geometric means for C max and AUC 0-τ for R-warfarin increased by no more than 8% when warfarin 25 mg was administered in the presence of dapagliflozin 10 mg relative to those observed following administration of warfarin 25 mg alone (Table 3 ). The 90% CIs for the ratio of the geometric means for C max and AUC 0-τ for R-warfarin, with and without dapagliflozin, were all within the usual no-effect interval (Table 3 
Pharmacodynamics of Warfarin
The pharmacodynamics of warfarin were unaffected by the co-administration of dapagliflozin ( (Table 4 ). The 90% CI for the ratio of INR max and AUC (INR) between treatments fell within the usual no-effect range.
Safety Profile
Each drug and drug combination was well tolerated by the healthy subjects in these two studies. No serious adverse events, deaths, clinically relevant changes in vital signs or 12-lead electrocardiograms, or changes in physical examination findings were related to any of the study treatments. One subject experienced a serious adverse event that was not attributed to study treatment (psychiatric hospitalization) 24 days after being withdrawn Dapagliflozin is under development for T2DM
and improves glycemic parameters in treatmentnaive patients [14] , as well as in those requiring oral antihyperglycemic drugs [13, 14, 36] or insulin [16] . As many of these patients, in particular those requiring insulin, would be expected to require cardiovascular drugs, it was necessary to establish the potential for interaction between dapagliflozin and commonly prescribed cardiovascular medications. This study evaluated the interaction of dapagliflozin with four commonly prescribed drugs, simvastatin, valsartan, warfarin, and digoxin.
The pharmacokinetic profile of dapagliflozin, as determined in study 1, was consistent with profiles seen in previous monotherapy studies performed in healthy subjects [22] , and the co-administration of either simvastatin or valsartan had no impact on the C max of dapagliflozin or on the overall exposure to dapagliflozin, as assessed by AUC 0-τ . Similarly, the co-administration of dapagliflozin did not alter the C max of simvastatin. The 90% CI was within the usual US FDA-defined no-effect range of 0.80-1.25 [37] , and the geometric mean ratio of simvastatin AUC 0-τ was within the usual no-effect range, while the upper limit value was not within the no-effect range (1.40). Furthermore, the co-administration of dapagliflozin with simvastatin did not alter the C max of simvastatin acid, although the geometric mean ratio of AUC 0-τ was increased by 30%.
Co-administration of dapagliflozin did not appear to alter the C max or AUC 0-τ of valsartan. Once-daily oral dapagliflozin has been shown to improve glycemic control without any increase in daily insulin requirements and also led to weight loss in patients with T2DM poorly controlled with insulin [16, 38] . Patients such as these, with an elevated risk for cardiovascular disease, may benefit from insulin-independent approaches to controlling hyperglycemia, such as SGLT2 inhibition. 
